Krystal Biotech, Inc.
NMS: KRYSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Krystal Biotech, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get KRYS Z-Score →About Krystal Biotech, Inc.
Healthcare
Biotechnology
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
📊 Fundamental Analysis
Krystal Biotech, Inc. demonstrates exceptional profitability, with a profit margin of 52.6%.
The company recently reported 17.5% revenue growth, which is well above average for the Healthcare sector.
Return on Equity (ROE) is 18.9%, which exceeds the Healthcare sector average, reflecting efficient capital allocation.
At a current price of $259.00, KRYS currently sits at the 78th percentile of its 52-week range (Range: $122.80 - $298.30).
💰 Valuation Insight
KRYS trades at a 51.5% premium to the sector average PE of 25.00. Analysts expect earnings growth, as indicated by a lower forward PE.
🏥 Financial Health
✅
Profit Margin
Excellent
🔴
Debt/Equity
Elevated
✅
Revenue Growth
Excellent
⚠️
Return on Equity
Moderate
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$7.62B
Trailing P/E
37.87
Forward P/E
24.48
Beta (5Y)
0.54
52W High
$298.30
52W Low
$122.80
Avg Volume
288K
Day High
Day Low